vs

Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $75.1M, roughly 1.0× SAUL CENTERS, INC.). SAUL CENTERS, INC. runs the higher net margin — 8.7% vs -9.6%, a 18.3% gap on every dollar of revenue. On growth, SAUL CENTERS, INC. posted the faster year-over-year revenue change (10.6% vs -16.8%). Over the past eight quarters, SAUL CENTERS, INC.'s revenue compounded faster (6.2% CAGR vs -8.4%).

Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

BFS vs BIOX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.0× larger
BIOX
$77.6M
$75.1M
BFS
Growing faster (revenue YoY)
BFS
BFS
+27.5% gap
BFS
10.6%
-16.8%
BIOX
Higher net margin
BFS
BFS
18.3% more per $
BFS
8.7%
-9.6%
BIOX
Faster 2-yr revenue CAGR
BFS
BFS
Annualised
BFS
6.2%
-8.4%
BIOX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BFS
BFS
BIOX
BIOX
Revenue
$75.1M
$77.6M
Net Profit
$6.5M
$-7.4M
Gross Margin
46.8%
Operating Margin
65.4%
9.3%
Net Margin
8.7%
-9.6%
Revenue YoY
10.6%
-16.8%
Net Profit YoY
-19.6%
-20.2%
EPS (diluted)
$0.15
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFS
BFS
BIOX
BIOX
Q4 25
$75.1M
Q3 25
$72.0M
$77.6M
Q2 25
$70.8M
Q1 25
$71.9M
$60.6M
Q4 24
$67.9M
$98.8M
Q3 24
$67.3M
$93.3M
Q2 24
$66.9M
Q1 24
$66.7M
$84.0M
Net Profit
BFS
BFS
BIOX
BIOX
Q4 25
$6.5M
Q3 25
$10.5M
$-7.4M
Q2 25
$10.7M
Q1 25
$9.8M
$-1.6M
Q4 24
$8.1M
$605.2K
Q3 24
$14.5M
$-6.2M
Q2 24
$14.4M
Q1 24
$13.6M
$9.8M
Gross Margin
BFS
BFS
BIOX
BIOX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
73.6%
40.2%
Q2 24
74.2%
Q1 24
72.8%
50.8%
Operating Margin
BFS
BFS
BIOX
BIOX
Q4 25
65.4%
Q3 25
69.1%
9.3%
Q2 25
68.7%
Q1 25
66.5%
1.5%
Q4 24
82.9%
14.5%
Q3 24
72.8%
2.5%
Q2 24
75.0%
Q1 24
72.4%
15.7%
Net Margin
BFS
BFS
BIOX
BIOX
Q4 25
8.7%
Q3 25
14.6%
-9.6%
Q2 25
15.1%
Q1 25
13.6%
-2.6%
Q4 24
11.9%
0.6%
Q3 24
21.5%
-6.6%
Q2 24
21.6%
Q1 24
20.4%
11.6%
EPS (diluted)
BFS
BFS
BIOX
BIOX
Q4 25
$0.15
Q3 25
$0.32
$-0.12
Q2 25
$0.33
Q1 25
$0.29
$-0.02
Q4 24
$0.22
$0.00
Q3 24
$0.48
$-0.10
Q2 24
$0.48
Q1 24
$0.45
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFS
BFS
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$8.7M
$15.5M
Total DebtLower is stronger
$468.4M
Stockholders' EquityBook value
$307.8M
$288.3M
Total Assets
$2.2B
$734.9M
Debt / EquityLower = less leverage
1.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFS
BFS
BIOX
BIOX
Q4 25
$8.7M
Q3 25
$11.8M
$15.5M
Q2 25
$5.3M
Q1 25
$6.5M
$38.5M
Q4 24
$10.3M
$29.2M
Q3 24
$7.2M
$32.3M
Q2 24
$6.9M
Q1 24
$7.1M
$16.4M
Total Debt
BFS
BFS
BIOX
BIOX
Q4 25
$468.4M
Q3 25
$1.6B
Q2 25
$1.6B
Q1 25
$1.5B
Q4 24
$455.8M
Q3 24
$1.5B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
BFS
BFS
BIOX
BIOX
Q4 25
$307.8M
Q3 25
$316.6M
$288.3M
Q2 25
$322.4M
Q1 25
$328.4M
$345.0M
Q4 24
$335.8M
$346.3M
Q3 24
$341.8M
$346.0M
Q2 24
$345.7M
Q1 24
$347.1M
$348.5M
Total Assets
BFS
BFS
BIOX
BIOX
Q4 25
$2.2B
Q3 25
$2.2B
$734.9M
Q2 25
$2.1B
Q1 25
$2.1B
$798.2M
Q4 24
$2.1B
$835.2M
Q3 24
$2.1B
$827.3M
Q2 24
$2.1B
Q1 24
$2.0B
$836.1M
Debt / Equity
BFS
BFS
BIOX
BIOX
Q4 25
1.52×
Q3 25
5.02×
Q2 25
4.85×
Q1 25
4.70×
Q4 24
1.36×
Q3 24
4.37×
Q2 24
4.17×
Q1 24
4.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFS
BFS
BIOX
BIOX
Operating Cash FlowLast quarter
$99.8M
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
15.35×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFS
BFS
BIOX
BIOX
Q4 25
$99.8M
Q3 25
$20.6M
$14.4M
Q2 25
$26.6M
Q1 25
$30.4M
$23.3M
Q4 24
$121.2M
$-5.4M
Q3 24
$26.5M
$5.2M
Q2 24
$32.1M
Q1 24
$33.8M
$-17.4M
Free Cash Flow
BFS
BFS
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$-28.3M
Q2 24
$-12.5M
Q1 24
$-11.7M
FCF Margin
BFS
BFS
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-42.1%
Q2 24
-18.7%
Q1 24
-17.6%
Capex Intensity
BFS
BFS
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
81.5%
Q2 24
66.7%
Q1 24
68.3%
Cash Conversion
BFS
BFS
BIOX
BIOX
Q4 25
15.35×
Q3 25
1.97×
Q2 25
2.48×
Q1 25
3.10×
Q4 24
14.98×
-8.85×
Q3 24
1.83×
Q2 24
2.22×
Q1 24
2.48×
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons